Literature DB >> 1090521

Inhibition of Escherichia coli by bovine colostrum and post-colostral milk. I. Complement-mediated bactericidal activity of antibodies to a serum susceptible strain of E. coli of the serotype O 111.

B Reiter, J H Brock.   

Abstract

Bovine colostral whey diulted in unheated bovine milk or in Kolmer saline containing 5 per cent pre-colostral calf serum was bactericidal for Escherichia coli NCTC 9703 (serotype O 111). Whey diluted in saline without pre-colostral calf serum was inactive. Bactericidal activity was abolished by heating at 56 degrees for 30 minutes or by pre-incubating with N-acetyl-L-tyrosine ethylester, indicating that complement present in milk or pre-colostral calf serum was involved in the bactericidal activity. Undiluted colostral whey was inactive even in the presence of up to 20 per cent pre-colostral calf serum, probably due to a prozone effect. Milk heated at 80 degrees for 10 minutes was also shown to have a limited anti-complementary effect. Post-colostral milk from some cows had bactericidal activity, whereas similar milks from other cows were either inactive or active only after addition of pre-colostral calf serum, indicating that antibodies to E. coli or complement or both may or may not be present in the post-colostral milk of different cows. The implications of these findings in relation to the bacterial flora of the intestinal tract of neonates are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1090521      PMCID: PMC1445769     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  BIOPHYSICAL AND IMMUNOLOGICAL STUDIES ON BOVINE IMMUNE GLOBULINS WITH EVIDENCE FOR SELECTIVE TRANSPORT WITHIN THE MAMMARY GLAND FROM MATERNAL PLASMA TO COLOSTRUM.

Authors:  A E PIERCE; A FEINSTEIN
Journal:  Immunology       Date:  1965-01       Impact factor: 7.397

Review 2.  Breast milk and defence against infection in the newborn.

Authors:  L A Hanson; J Winberg
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

3.  The bactericidal action of immunoglobulin A.

Authors:  D W Burdon
Journal:  J Med Microbiol       Date:  1973-05       Impact factor: 2.472

4.  Shared antigens between heterologous bacterial species.

Authors:  P Minden; J K McClatchy; R S Farr
Journal:  Infect Immun       Date:  1972-10       Impact factor: 3.441

Review 5.  The demonstration and function of antibodies in the gastrointestinal tract.

Authors:  D J Shearman; D M Parkin; D B McClelland
Journal:  Gut       Date:  1972-06       Impact factor: 23.059

6.  Bacterial and viral coproantibodies in breast-fed infants.

Authors:  J F Kenny; M I Boesman; R H Michaels
Journal:  Pediatrics       Date:  1967-02       Impact factor: 7.124

7.  Secretory IgA, a major immunoglobulin in most bovine external secretions.

Authors:  J P Mach; J J Pahud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

8.  Complement activity of sheep body fluids and human guinea-pig colostrum.

Authors:  W E Jonas; S Broad
Journal:  Res Vet Sci       Date:  1972-03       Impact factor: 2.534

9.  Bacterial inhibitors in milk and other biological fluids.

Authors:  B Reite; J D Oram
Journal:  Nature       Date:  1967-10-28       Impact factor: 49.962

10.  Common antigenic determinant in a rumen organism and in salmonellae containing the antigen O4.

Authors:  M E Sharpe; B Reiter
Journal:  Appl Microbiol       Date:  1972-10
View more
  11 in total

Review 1.  Immune components of colostrum and milk--a historical perspective.

Authors:  Thomas T Wheeler; Alison J Hodgkinson; Colin G Prosser; Stephen R Davis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-11-09       Impact factor: 2.673

2.  Nonspecific bactericidal activity of the lactoperoxidases-thiocyanate-hydrogen peroxide system of milk against Escherichia coli and some gram-negative pathogens.

Authors:  B Reiter; V M Marshall; C G Rosén
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

3.  Stimulation of the development of bacteriostatic activity of guinea-pig milk against Escherichia coli.

Authors:  S Stephens; J M Dolby
Journal:  Br J Exp Pathol       Date:  1978-04

4.  Inhibition of Escherichia coli by bovine colostrum and post-colostral milk. II. The bacteriostatic effect of lactoferrin on a serum susceptible and serum resistant strain of E. coli.

Authors:  B Reiter; J H Brock; E D Steel
Journal:  Immunology       Date:  1975-01       Impact factor: 7.397

5.  Adsorption in vitro to Escherichia coli of antibodies and other proteins in bovine serum and colostrum and its effects on the production of E. coli agglutinins.

Authors:  E D Steel
Journal:  Immunology       Date:  1975-07       Impact factor: 7.397

Review 6.  Oligosaccharides and glycoconjugates in human milk: their role in host defense.

Authors:  D S Newburg
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

7.  Antibacterial effect of bovine milk antibody against Escherichia coli in a mouse indigenous infection model.

Authors:  K Nomoto; Y Matsuoka; K Hayakawa; M Ohwaki; T Kan; Y Yoshikai; K Nomoto
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

8.  Role of antibody and enterobactin in controlling growth of Escherichia coli in human milk and acquisition of lactoferrin- and transferrin-bound iron by Escherichia coli.

Authors:  J H Brock; M G Pickering; M C McDowall; A G Deacon
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

Review 9.  Inhibitors of complement activity in human breast-milk: a proposed hypothesis of their physiological significance.

Authors:  M O Ogundele
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

10.  Antibodies against invasive phenotype-specific antigens increase Mycobacterium avium subspecies paratuberculosis translocation across a polarized epithelial cell model and enhance killing by bovine macrophages.

Authors:  Jamie L Everman; Luiz E Bermudez
Journal:  Front Cell Infect Microbiol       Date:  2015-08-07       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.